Hemab Therapeutics (COAG) stock
COAG · Hemab Therapeutics Holdings Inc. · NASDAQ
- Market cap
- $1.84B
- Shares out
- 46.7M
What is the latest news on COAG stock?
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will participate in the following upcoming investor conferences and host investor meetings. 2026 Jefferies Global Healthcare ConferenceFireside Chat: Tuesday, November 17, 2026, at 5:00 PM GMTLocation: London, United Kingdom 9th Annual Evercore Healthcare ConferenceFireside Chat: Tuesday, December 1, 2026, at 3:00 PM ETLocation: Coral Gables, FL A live w
All COAG newsWhen does Hemab Therapeutics report earnings?
Hemab Therapeutics last reported on Nov 10, 2026, the date it announced on Nov 3, 2026.
COAG earnings historyWho owns the most COAG stock?
Ra Capital Management, L.p. was the largest reported holder of COAG at the end of Q2 2026, with 7,808,627 shares worth $286.8 million. Next came Novo Holdings A/S ($153.6 million) and FMR LLC ($135.8 million). In all, 55 institutions reported $1.3 billion of COAG in their 13F filings.
All COAG fund holdersLatest news
8 items- PRHemab Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will participate in the following upcoming investor conferences and host investor meetings. 2026 Jefferies Global Healthcare ConferenceFireside Chat: Tuesday, November 17, 2026, at 5:00 PM GMTLocation: London, United Kingdom 9th Annual Evercore Healthcare ConferenceFireside Chat: Tuesday, December 1, 2026, at 3:00 PM ETLocation: Coral Gables, FL A live w
- SECSEC Form 10-Q filed by Hemab Therapeutics Holdings Inc.10-Q - Hemab Therapeutics Holdings, Inc. (0002114044) (Filer)
- SECHemab Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Hemab Therapeutics Holdings, Inc. (0002114044) (Filer)
- PRHemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateDosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone Announced data showing HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model; data to be presented at the 68th ASH Annual Meeting and Exposition in December 2026 Announced first clinical data for sutacimig in Factor VII deficiency (FVIID), showing shortening of prothrombin time by more than 50% in both participants and ~5x accumulation of endogenous FVII(a) in the participant with PK/PD data, after a single dose; updated Phase 2b data to be presented at ASH in December 2026 Initiated SOLARA, a p
- PRHemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann ThrombastheniaHemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia Single-arm design with a 24-week run-in followed by 48 weeks of treatment; primary endpoint is annualized treated bleed rate CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the initiation of SOLARA, a pivotal Phase 3 trial evaluating sutacimig (HMB-001) as a potential prophylactic treatment for people with Glanzmann thro
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Hemab Therapeutics Holdings Inc.SCHEDULE 13G/A - Hemab Therapeutics Holdings, Inc. (0002114044) (Subject)
- PRHemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and ExpositionFirst clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study Preclinical data show HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model of menstrual bleeding CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced two presentations showcasing progress from multiple pipeline pr
- PRHemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that it will host a conference call on Tuesday, November 10, at 8:00 a.m. ET to discuss its financial results and provide a corporate update for the third quarter ended September 30, 2026. Listeners can register for the webcast on the investors page of the company’s website (https://ir.hemab.com/) or directly through this link. Analysts wishing to participate in the question and answer session should use this
COAG rankings
- Other3(38%)
- Earnings2(25%)
- SEC Filings2(25%)
- 13D/G1(13%)
Hemab Therapeutics Holdings Inc. (COAG) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 8 wire items for COAG, including 3 press releases and news items, 2 earnings updates and 2 SEC filings. The most recent was published Nov 11, 2026.
COAG FAQ
6 questionsWhat does Hemab Therapeutics Holdings Inc. do?
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the...Where does COAG stock trade?
Hemab Therapeutics Holdings Inc. (COAG) is listed on NASDAQ.What sector and industry is COAG in?
Hemab Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Hemab Therapeutics Holdings Inc. go public?
Hemab Therapeutics Holdings Inc. (COAG) completed its IPO in 2026.What companies are similar to COAG?
Notable peers in the same industry include SNY (Sanofi), PFE (Pfizer Inc.), NVO (Novo Nordisk A/S), TAK (Takeda Pharmaceutical Company Limited), VRTX (Vertex Pharmaceuticals Incorporated). Compare COAG side-by-side with any of them on Quantisnow.How can I track COAG on Quantisnow?
Quantisnow aggregates Hemab Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COAG to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change